España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
David Nierengarten
Myokardia Analysts See Mavacamten As Blockbuster Opportunity For Bristol-Myers Squibb
Wedbush Starts Iveric Bio Coverage With Bullish Rating On Zimura's Upcoming Pivotal Study
Wedbush: Investors Largely Underappreciating AnaptysBio
Wedbush Starts Iveric Bio Coverage With Bullish Rating On Zimura's Upcoming Pivotal Study
Wedbush: Investors Largely Underappreciating AnaptysBio
Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows
Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade
Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows
Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade
Wedbush: Trajectory For Stemline Therapeutics' Blood Cancer Drug Priced Into Stock
FDA Delays Selinexor Approval By 3 Months — So Why Is Karyopharm Ripping Higher?
Read More...
David Nierengarten Recent News
Analysts Slash KaryoPharm Price Targets By Over 50% After Adcom Setback
Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?
Wedbush Moves To The Sidelines On Tesaro Following Glaxo Deal
Wedbush Bets On Magenta Therapeutics, Projects Rewards If Stem Cell Technology Successful
'We Expect A Quick Resolution': Despite Partial Clinical Hold On Epizyme's Drug Candidate, Wedbush Stays Bullish
Analyst: Spark Therapeutics' $850K Blindness Drug Has Smaller-Than-Expected Market
Wedbush Rates Kura Oncology Outperform As Catalysts Loom
Endocyte Shares Up More Than 100% In 2 Days, But Analyst Sees Even More Upside Possible
A Data-Rich Year Has Analysts Accepting Their Fate Therapeutics Trade
Wedbush Cuts TESARO Target By 18% Following SOLO-2 Results
Wedbush Asks: How Does Kite Pharma's ZUMA-1 Compare To Juno's TRANSCEND?
Bluebird Bio Shares Could See Value Fly To $95 As 2017 Will Be A 'Catalyst-Filled Year'
Analyst Breaks Down Bluebird Bio's Better-Than-Expected Clinical Results
Good And Bad News from Epizyme; Wedbush Analyst Weighs In
Tailwinds Continue To Hold The Street's Gaze Toward Bluebird Bio Aloft
Wedbush Raises TESARO Price Target From $107 To $139
Audentes Therapeutics Initiated Overweight At Wedbush
Bluebuird Bio Crashes Nearly 30%: What's Next?
How Wedbush Sees The Alexion–Synageva Deal